Skip to main content

Recommended Treatment for STIs More Likely in Public Versus Private Health Care Settings

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, April 30, 2024 -- Individuals seen for sexually transmitted infections (STIs) by clinicians in a private U.S. health care setting are less likely to receive recommended treatment than those seen in a public health clinic, according to a study published online in the May issue of Sexually Transmitted Diseases.

Brian E. Dixon, Ph.D., from Indiana University in Indianapolis, and colleagues compared treatment rates for laboratory-confirmed Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC; 2016 to 2020) among public and private providers. Data included linked electronic health records and Medicaid claims.

The researchers found that 82.2 percent of initial CT and 63.0 percent of initial GC episodes received U.S. Centers for Disease Control and Prevention-recommended treatment. Across the five-year period, the public STI clinic treated >90 percent of CT and GC cases consistently, while private providers were significantly less likely to treat first episodes for CT (79.6 percent) and GC (53.3 percent). A higher likelihood of recommended treatment was associated with being male, being HIV-positive, and identifying as Black or multiracial. While all CT cases with treatment occurred per guidelines, 10.8 percent of GC cases received nonrecommended treatment.

"Although these treatment rates are higher than previous studies, there remain significant gaps in STI treatment that require intervention from public health," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Rise in Drug-Resistant Gonorrhea in China May Pose Global Threat

THURSDAY, March 28, 2024 -- Cases of a strain of highly antibiotic-resistant gonorrhea that first emerged in China in 2016 have tripled there in just five years, according to...

2022 Saw More Than 2.5 Million Cases of Chlamydia, Gonorrhea, Syphilis

FRIDAY, Feb. 2, 2024 -- More than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2022, with concerns centering around syphilis and...

Teen Pregnancy, Sexual Health Care Use Lower Than Expected During Pandemic

FRIDAY, Feb. 2, 2024 -- During the COVID-19 pandemic, population-level rates of adolescent pregnancy and sexual health-related care utilization were lower than expected, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.